NURTEC ODT

USDailyMed:Rimegepant AU:B1 N02CD06(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate 1289023-67-1 51049968 DB12457 27289072 997WVV895X D10663D10662 ChEMBL2178422 DTXSID70156003 Interactive image N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(2​​​‍​​‍​​​​‍​​‍‍4(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N Rimegepant, sold under the brand nameNurtec ODTamong others, is amedicationused for the acute treatment ofmigrainewith or withoutaurain adults and the prophylactic treatment of episodic migraine in adults.It is takenby mouthto dissolve on orunder the tongue.It works by blockingCGRP receptors. In the United States, rimegepant was approved for treating acute migraine in February 2020,and its approval was extended to preventing episodic migraine in June 2021.It is produced and marketed byPfizer.In March 2021, rimegepant was approved for medical use in theUnited Arab Emiratesand inIsrael.It was approved for medical use in Canada in December 2023.In the United Kingdom, rimegepant is approved by NICE for the prophylaxis and treatment of acute migraine in adults.In 2023, it was the 206th most commonly prescribed medication in the United States, with more than 2million prescriptions.